Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma by Farahi, Neda et al.
A S S O C I A T I O N S T U D I E S A R T I C L E
Neutrophil-mediated IL-6 receptor trans-signaling and
the risk of chronic obstructive pulmonary disease
and asthma
Neda Farahi1,†, Ellie Paige2,†, Jozef Balla1, Emily Prudence1,
Ricardo C. Ferreira3, Mark Southwood1, Sarah L. Appleby1, Per Bakke4,
Amund Gulsvik4, Augusto A. Litonjua5, David Sparrow6, Edwin K. Silverman5,
Michael H. Cho5, John Danesh2,7,8,9, Dirk S. Paul2, Daniel F. Freitag2,*,‡ and
Edwin R. Chilvers1,‡
1Division of Respiratory Medicine, Department of Medicine, University of Cambridge School of Clinical
Medicine, Cambridge CB2 0QQ, UK, 2Department of Public Health and Primary Care, Strangeways Research
Laboratory, University of Cambridge CB1 8RN, Cambridge, UK, 3JDRF/Wellcome Trust Diabetes and
Inflammation Laboratory, Nuffield Department of Medicine, Wellcome Trust Centre for Human Genetics,
University of Oxford, Oxford OX3 7BN, UK, 4Department of Clinical Science, University of Bergen, Bergen 5021,
Norway, 5Brigham and Women’s Hospital and Harvard Medical School, Boston 02115, MA, USA, 6VA Boston
Healthcare System and School of Medicine, Boston University, Boston 02132, MA, USA, 7British Heart
Foundation Centre of Excellence, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK,
8NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Cambridge, UK and 9Wellcome
Trust Sanger Institute, Hinxton CB10 1SA, UK
*To whom correspondence should be addressed at: Email: dff21@medschl.cam.ac.uk
Abstract
The Asp358Ala variant in the interleukin-6 receptor (IL-6R) gene has been implicated in asthma, autoimmune and
cardiovascular disorders, but its role in other respiratory conditions such as chronic obstructive pulmonary disease (COPD)
has not been investigated. The aims of this study were to evaluate whether there is an association between Asp358Ala and
COPD or asthma risk, and to explore the role of the Asp358Ala variant in sIL-6R shedding from neutrophils and its pro-
inflammatory effects in the lung. We undertook logistic regression using data from the UK Biobank and the ECLIPSE COPD
cohort. Results were meta-analyzed with summary data from a further three COPD cohorts (7,519 total cases and 35,653 total
controls), showing no association between Asp358Ala and COPD (OR¼1.02 [95% CI: 0.96, 1.07]). Data from the UK Biobank
showed a positive association between the Asp358Ala variant and atopic asthma (OR¼1.07 [1.01, 1.13]). In a series of in vitro
studies using blood samples from 37 participants, we found that shedding of sIL-6R from neutrophils was greater in carriers
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of the Asp358Ala minor allele than in non-carriers. Human pulmonary artery endothelial cells cultured with serum from
homozygous carriers showed an increase in MCP-1 release in carriers of the minor allele, with the difference eliminated upon
addition of tocilizumab. In conclusion, there is evidence that neutrophils may be an important source of sIL-6R in the lungs,
and the Asp358Ala variant may have pro-inflammatory effects in lung cells. However, we were unable to identify evidence
for an association between Asp358Ala and COPD.
Introduction
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been
implicated in a range of complex chronic diseases. Evidence has
been building that one functional variant Asp358Ala (rs2228145)
in the IL-6 receptor (IL-6R) gene regulates IL-6 signaling (1).
Previous studies have shown that this variant is associated with
a decreased risk of coronary heart disease (CHD) (2–4), abdom-
inal aortic aneurysm (5), atrial fibrillation (6), rheumatoid arth-
ritis (7) and type 1 diabetes (1), but an increased risk of atopic
dermatitis (8) and asthma (9).
One hypothesis to explain the varying directional effects of
the IL-6R variant on disease risk is based on the opposing effects
of the variant on IL-6 classic signaling and trans-signaling. IL-6
signaling occurs via two distinct pathways, designated as ‘clas-
sical’ signaling and ‘trans-signaling’. In the classical signaling
binding of IL-6 to the membrane bound IL-6 receptor (mIL-6R)
causes recruitment of two molecules of the signal-transducing
receptor glycoprotein 130 (gp130). Homodimerisation of the
gp130 receptors leads to phosphorylation of transcription fac-
tors STAT1 or STAT3 by the Janus kinase family (JAK1, JAK2,
TYK2), as well as activation of the mitogen-activated protein
kinase (MAPK) cascade and the phosphoinositide 3-kinase
(PI3K) cascade (10). These downstream pathways can also be
activated by IL-6 trans-signaling via the generation of a soluble
form of the IL-6 receptor (sIL-6R), which forms a complex with
IL-6 and gp130. While sIL-6R can be released following alterna-
tive splicing of the IL-6R mRNA, the majority of circulating sIL-
6R is generated by ADAM10- and ADAM17-mediated proteolysis
of the mIL-6R (11). The substitution of alanine for aspartate in
position 358 of the IL-6R gene results in more efficient proteo-
lytic cleavage of mIL-6R (12). This results in decreased levels of
mIL-6R, which is involved in classic signaling, and increased
levels of soluble sIL-6R, which is involved in trans-signaling (1).
IL-6R classic signaling occurs only in leukocytes and hepato-
cytes which express the mIL-6R (13), and there is evidence that
the down-regulation of classic signaling in people with one or
two copies of the minor allele (C) leads to the observed
decreased risk of diseases such as CHD (1). In IL-6 trans-signal-
ing, sIL-6R bound to IL-6 stimulates gp130 (13), which is widely
expressed, including in lung cells. Since sIL-6R can trigger IL-6
signaling in cells normally unresponsive to IL-6, trans-signaling
has been implicated in the pathogenesis of a number of inflam-
matory diseases.
Higher levels of sIL-6R have been found in sputum and bron-
choalveolar lavage fluid (BALF) of people with asthma or chronic
obstructive pulmonary disease (COPD) compared to healthy
controls (14,15). Additionally, previous studies have shown as-
sociations between polymorphisms in the IL-6 gene and
increased risk of COPD—although not at genome-wide levels of
statistical significance (16). Combined with the replicated find-
ing that rs2228145 is associated with asthma and asthma sever-
ity (9,17), this led us to hypothesize that the Asp358Ala
functional variant may be associated with other respiratory
conditions such as COPD. Current evidence suggests that neu-
trophils are involved in COPD and also occur in greater
quantities in the BALF of people with severe asthma or smokers
with asthma (18). Thus, we hypothesized that neutrophils are a
possible source of sIL-6R in the lungs and may contribute to
pathogenic IL-6R trans-signaling in chronic respiratory
diseases.
In the present study, we first investigated the relationship
between the IL-6R variant and the risk of COPD, using genetic
data from the UK Biobank, a large-scale UK-wide prospective co-
hort study of middle-aged volunteers, along with several other
well-phenotyped COPD cohorts with genetic information on the
functional IL-6R variant and its proxies. Second, we sought to
replicate the association between the IL-6R functional variant
and an increased risk of asthma and allergy-related diseases
using data collected from participants in the UK Biobank. Third,
we conducted in vitro experiments to examine whether the IL-
6R variant is associated with increased shedding of sIL-6R from
neutrophils and whether IL-6R trans-signaling is pro-
inflammatory in the lung micro-environment.
Results
Since previous studies have shown higher levels of serum IL-6
in people with COPD compared to those without COPD (19–22),
we first examined the association between rs2228145 and base-
line serum IL-6 level in the ECLIPSE study, finding an increase in
IL-6 level per copy of the minor allele after adjustment for age,
COPD status, smoking status, smoking amount and ancestry
(b¼ 0.15 [95% CI: 0.08, 0.23]). We found no evidence of an associ-
ation between rs2228145 and COPD when the results from the
UK Biobank (Supplementary Material, Table S1) and the COPD
case-control cohorts were meta-analyzed (OR¼ 1.02 [0.96, 1.07];
Fig. 1). There was no evidence of heterogeneity between the
studies contributing to the meta-analysis (I2¼0.0%, P¼ 0.859).
Results were consistent for the association between rs4129267
(proxy variant) and COPD (OR¼ 1.02 [0.95, 1.08]; Supplementary
Material, Fig. S1), and also when meta-analyzed using random-
effects meta-analysis (data not shown).
Using UK Biobank data, we found no evidence of an overall
association between rs2228145 and risk of asthma (OR¼ 1.02
[95% CI: 0.99, 1.05]; Table 1) but when comparing asthma pheno-
types, we observed an increased risk of atopic asthma com-
pared to non-atopic asthma per copy of the minor allele of
rs2228145 (OR¼ 1.07 [1.01, 1.13]; Table 1). The rs2228145 variant
was also associated with an increased risk of allergy-related dis-
ease phenotypes (OR¼ 1.08 [1.04, 1.11]; Table 2). These results
persisted in analyses that used increasingly restrictive sets of
exclusion criteria based on history of inflammatory-related ill-
ness (CHD, stroke, diabetes or cancer) and other respiratory ill-
nesses (COPD, asthma (where relevant), pneumonia or
bronchiectasis). The results of this new human genetic data on
COPD and asthma risk in the UK Biobank population are shown
in context of other known disease risks associated with
rs2228145 in Figure 2.
We further assessed whether the rs2228145 variant was
associated with decreased airway function or with an increased
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risk of airway obstruction using spirometry measures from the
UK Biobank. We found no evidence of an association between
rs2228145 and airway function or obstruction, including when
the results were stratified by asthma and COPD status and
examined separately by smoking status (Supplementary
Material, Tables S2 and S3).
To elucidate the association of the Asp358Ala non-
synonymous variant with asthma and allergy-related pheno-
types, we next examined the molecular mechanism through a
series of in vitro experiments. As previously shown, the
Asp358Ala variant was associated with increased concentra-
tions of sIL-6R in the serum (Fig. 3A). We then investigated the
expression of mIL-6R in human peripheral blood-derived neu-
trophils. We demonstrated the expression of mIL-6R in freshly
isolated neutrophils using confocal microscopy (Fig. 3B), flow
cytometry (Fig. 3C) and immunocytochemistry (Fig. 3D).
Expression of IL-6R in peripheral blood mononuclear cells
(PBMCs) was used as a positive control for flow cytometry ana-
lysis. These results suggest that neutrophils can provide a
source of sIL-6R in the plasma.
Given that previous work (23) has described shedding of IL-
6R from stimulated neutrophils, we sought to compare sIL-6R
release between rs2228145 C/C homozygous, A/C heterozygous
and A/A homozygous individuals. Upon stimulation with either
the physiological agonist N-formyl-methionyl-leucyl-phenyl-
alanine (fMLP) or phorbol 12-myristate 13-acetate (PMA), sIL-6R
release from neutrophils was significantly greater in C/C homo-
zygous donors compared to A/A homozygous donors (Figs 3E
and F). This effect was not observed in PBMCs (Fig. 3G). Taken
together, these results are indicative of a genotype-dependent
association of sIL-6R release from neutrophils.
IL-6 trans-signaling has been previously identified as pro-
inflammatory in smooth muscle cells, mesothelial cells and
endothelial cells (24–26). To assess the effect of sIL-6R trans-
signaling in the lung endothelium, we measured the expres-
sion of various cell adhesion markers and monocyte chemo-
attractant protein-1 (MCP-1) release by human pulmonary
artery endothelial cells (HPAECs) following treatment with
recombinant IL-6 and sIL-6R alone or in combination. TNF-a
treatment was used as a positive control. Stimulation with
either IL-6 or sIL-6R alone did not alter intercellular adhesion
molecule 1 (ICAM-1) levels detected by flow cytometry after
24 h (Fig. 4A). A stimulation period of 24 h was chosen as the
MCP-1 release by HPAECs (using IL-6 and sIL-6R) was demon-
strated to be maximal at this time-point (data not shown).
However, IL-6 in combination with sIL-6R significantly
increased the expression of ICAM-1 and the release of MCP-1
by  2-fold in HPAECs (Figs 4B and C). The MCP-1 release was
suppressed in the presence of the anti-human IL-6R mono-
clonal antibody tocilizumab (Fig. 4D). There was no change in
the expression of vascular cell adhesion protein 1 (VCAM-1)
and E-selectin (Supplementary Material, Fig. S2). Human
bronchial epithelial cells did not enhance MCP-1 (data not
shown) or IL-8 release (Supplementary Material, Fig. S3) fol-
lowing combined IL-6 and sIL-6R stimulation.
Having shown the pro-inflammatory effect of IL-6 trans-
signaling in the lung endothelium, we next sought to test our
hypothesis that increased sIL-6R shedding by C/C individuals
is pro-inflammatory. We cultured HPAECs with serum from 8
A/A and 9 C/C participants and measured MCP-1 release after
24 h. As shown in Figure 5, incubation with serum from C/C
carriers resulted in no increase in the MCP-1 release compared
Figure 1. Forest plot showing the association between rs2228145 and the risk of COPD. CI¼, confidence interval; COPD¼, chronic obstructive pulmonary disease;
OR¼, odds ratio. Results are for current or former smokers and adjusted for age, ancestry principal components, and smoking amount. Fixed effects meta-analysis
using inverse-variance weighting. Sizes of the boxes are proportional to the number of cases.
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to A/A carriers (A/A serum; 13346195.6 pg/ml and C/C serum;
19776268.1 pg/ml, P¼ 0.06). The addition of A/A serum alone
resulted in MCP-1 concentrations comparable to that of un-
treated cells at 24 h (10306 319.7 pg/ml), suggesting that add-
ition of serum did not adversely affect the HPAECs. The
addition of IL-6 to the serum resulted in the increased MCP-1
release in both groups compared to serum alone, but signifi-
cantly more MCP-1 release from C/C carriers (A/A serum;
36046579.7 pg/ml and C/C serum; 47616232.4 pg/ml,
P¼ 0.009). This response was also replicated using lower IL-6
concentrations (10 ng/ml) (Supplementary Material, Fig. S4A).
There were no statistically significant differences in IL-6 or
MCP-1 concentrations between the C/C and A/A serum prior to
their addition to HPAECs (Supplementary Material, Fig. S4B
and C).Furthermore, incubation with tocilizumab reversed the
IL-6 mediated MCP-1 release in both groups to baseline levels
and, importantly, abolished the difference between the A/A
and C/C carriers (Fig. 5).
Discussion
Although there is considerable evidence that levels of sIL-6R are
increased in people with respiratory diseases such as asthma
and COPD, the genetic association between the Asp358Ala func-
tional variant in the IL-6R gene and COPD has not been specific-
ally assessed, and little is understood about the mechanisms
driving sIL-6 trans-signaling in the lung. In this study, we pro-
vide further evidence for the association of the Asp358Ala non-
synonymous variant with atopic asthma and a broad group of
allergy-related conditions, but not with COPD risk. Most import-
antly, we show, for the first time, an association between the
Asp358Ala variant and increased shedding of sIL-6R from
human neutrophils and provide evidence for a pro-
inflammatory effect of sIL-6 trans-signaling in human pulmon-
ary artery endothelial cells. We observed an increased release of
MCP-1 (a chemokine involved in inflammatory responses) from
lung endothelial cells after addition of serum from homozygous
carriers of the minor allele but not after addition of serum from
homozygous carriers of the major allele. This effect was blocked
with the addition of the anti-IL-6R monoclonal antibody tocili-
zumab, suggesting that the observed genotype-dependent re-
lease of MCP-1 occurred via IL-6 signaling pathways and not
through an alternative mechanism.
In contrast to our hypothesis, we found no association be-
tween the Asp358Ala variant and the risk of COPD. This was sur-
prising given reports of increased levels of sIL-6R in people with
COPD (15), and previous reports of associations of polymorphisms
in the IL-6 gene with this condition (16,27,28). Recent experimen-
tal evidence in mouse models supports the involvement of IL-6
trans-signaling in the development of emphysema via activation
of the mammalian target of rapamycin complex 1 (mTORC1)
pathway and that this is independent of the inflammatory re-
sponse (29). Based on this and previous work (30), the authors
hypothesized that IL-6R trans-signaling may contribute to lung
inflammation and the development of emphysema via two dis-
crete pathways. Firstly, they propose that sIL-6R acts via STAT3
activation to initiate lung inflammation (30) and, secondly,
through a pathway whereby sIL-6R activates mTORC1 and con-
tributes to the development of emphysema (29). It is known that
the Asp358Ala variant increases sIL-6 signaling, which activates
STAT3, a necessary component for inflammatory processes, via
the JAK-STAT and Ras-Raf-MAPK signaling pathways (31), how-
ever we are not aware of evidence that the Asp358Ala variant dir-
ectly activates the mTORC1 pathway. Furthermore, a previous
genome-wide association study (32) found no evidence of an as-
sociation between the rs2228145 variant and emphysema defined
using lung density images using the traditional definition of950
Hounsfield units with P value¼ 0.192, and borderline nominal sig-
nificance for the 15th percentile of the density histogram (P
value¼ 0.042).
There are two possible explanations for the results of our
study when considered in the context of this previous experi-
mental work. If the STAT3 and mTORC1 pathways are inde-
pendent, as has been suggested (30), then activation of the
mTORC1 pathway downstream of sIL-6R may require additional
Table 1. Adjusted odds ratios (95% CI) for the risk of asthma and atopic asthma per copy of the minor allele of rs2228145
Overall asthma Atopic vs. non-atopic asthma*
N cases/N controls OR (95% CI) P-value N cases/N controls OR (95% CI) P-value
Model 1 16,939/83,718 1.02 (1.00, 1.04) 0.096 5,318/8,551 1.05 (1.00, 1.11) 0.047
Model 2 13,591/65,183 1.02 (1.00, 1.05) 0.075 4,550/6,607 1.07 (1.01, 1.13) 0.031
Model 3 13,157/63,859 1.02 (0.99, 1.05) 0.126 4,405/6,396 1.07 (1.01, 1.13) 0.032
CI¼, confidence interval; CHD¼, coronary heart disease; OR¼, odds ratio.
*Atopic asthma defined as age of asthma onset before 30 years and having either a history of allergic conditions (hay fever, allergic rhinitis and eczema) or having never
smoked.
Notes: (1) UK Biobank data only. (2) Results adjusted for sex, age, smoking status and ancestry principal components. (3) Model 1 includes the full dataset with no re-
strictions based on history of disease; Model 2 excludes people with inflammatory-related illness (history of CHD, stroke, diabetes or cancer); and Model 3 excludes peo-
ple with inflammatory-related illness and those with other respiratory illnesses (chronic obstructive pulmonary disease, pneumonia or bronchiectasis).
Table 2. Adjusted odds ratios (95% CI) for the risk of allergy-related
conditions per copy of the minor allele of the rs2228145
N cases/N controls OR (95% CI) P-value
Model 1 24,112/57,643 1.06 (1.03, 1.08) 9.00 107
Model 2 20,223/43,796 1.07 (1.04, 1.09) 2.58 107
Model 3 19,850/42,807 1.08 (1.04, 1.11) 4.00 106
CI¼, confidence interval; CHD¼, coronary heart disease; OR¼, odds ratio.
Notes: (1) Allergy-related conditions include hay fever, allergic rhinitis and ec-
zema. (2) UK Biobank data only. (3) Results adjusted for sex, age, BMI, smoking
status, smoking amount and ancestry principal components. (4) Model 1 in-
cludes the full dataset with no restrictions based on history of disease; Model 2
excludes people with inflammatory-related illness (history of CHD, stroke, dia-
betes or cancer); and Model 3 excludes people with inflammatory-related illness
(history of CHD, stroke, diabetes or cancer) and those with other respiratory ill-
nesses (chronic obstructive pulmonary disease, asthma, pneumonia or
bronchiectasis).
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signals over and above increased levels of sIL-6R. This could ex-
plain why we found no evidence of an association between the
Asp358Ala variant and the risk of COPD, and why the previous
study (32) found no association between this same variant and
emphysema. That is, the variant might act as an instrumental
variable for exposure to increased levels of sIL-6R only.
Alternatively, our results could result from a lack of power to
detect an effect size as small as that observed. Our study was
only powered to find an odds ratio of greater than 1.075, so if
enhanced IL-6 trans-signaling does contribute to the pathogen-
esis of COPD, it is likely that this relationship is weaker than
that observed for asthma in previous studies and may therefore
be of limited clinical relevance.
In contrast to a previous genome-wide association study
that reported a 9% increased risk of asthma for carriers of the
minor allele of the rs4129267 variant (proxy for rs2228145) (9),
we found no overall association between the rs2228145 and
asthma (OR¼ 1.02 [0.99, 1.05]). Our study was powered to see an
effect size of 1.055 or greater, suggesting that the effect of this
variant on asthma was weaker in our study compared to this
previous study. However, it was also noted in the study by
Ferreira and colleagues (9) that this association appeared to be
restricted to atopic asthma, and our finding of an increased risk
of atopic asthma vs. non-atopic asthma (albeit using a proxy
measure) among carriers of the rs2228145 minor allele adds
some weight to these previous unconfirmed findings. We did
not have information on specific asthma phenotypes and in-
stead we used a carefully defined proxy for atopic asthma
(based on age of onset, history of allergies and smoking status
(33)). Further, our finding that the Asp358Ala variant is associ-
ated with an increased risk of allergy-related diseases is consist-
ent with a previous study showing an increased risk atopic
dermatitis (8). In contrast to a previous study (17), we found no
association between the Asp358Ala variant and decreased lung
function in asthmatic never-smokers, potentially due to differ-
ences in asthma phenotyping which was more rigorously char-
acterized using spirometry measures and bronchodilator
reversibility in the previous study.
Previous studies have shown sIL-6R levels in serum are
increased in people with asthma, particularly among those with
severe asthma phenotypes, and these sIL-6R levels are associ-
ated with decreased lung function (17). Neutrophils have been
identified as a potential source of sIL-6R in asthma (13).
Consistent with this hypothesis and with a previous study,
which showed that showed neutrophils can be stimulated to
shed sIL-6R in response to inflammatory cues (23), we have dir-
ectly shown that neutrophils shed sIL-6R and that this shedding
is increased in carriers of the Asp358Ala minor allele. Although
endothelial cells do not express the mIL-6R required for classic
signaling, they do express gp130 and can utilize sIL-6R (trans-
signaling) to secrete monocyte MCP-1, IL-8 and induce ICAM-1
expression (26,34). Our finding that IL-6/sIL-6R trans-signaling
increases MCP-1 release and ICAM-1 expression in lung endo-
thelial cells is consistent with findings from previous studies
that used human umbilical vein endothelial cells (34). In add-
ition to aiding monocyte recruitment, MCP-1 is known to induce
mast cell activation and LTC4 release in the airway (35), and
clinical studies have demonstrated that MCP-1 is up-regulated
during the endobronchial allergen challenge (36). Our study
thus extends previous work by showing that MCP-1 release
from lung endothelial cells is increased in carriers of the
Asp358Ala minor allele and can be blocked using the IL-6 inhibi-
tor tocilizumab, providing evidence of a pro-inflammatory effect
of IL-6 trans-signaling in the lung micro-environment. The only
previous study to examine the functional effect of the minor
variant on monocytes reported a genotype-dependent effect on
unstimulated PBMCs (13). In contrast, we found no genotype-
dependent effect on sIL-6R release from PBMCs; the reason for
Figure 2. Forest plot showing associations of rs2228145 (or proxy) with a range of human diseases. CI¼, confidence interval; COPD¼, chronic obstructive pulmonary dis-
ease; OR¼, odds ratio. OR plotted on log-scale.
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this discrepancy is unclear but may reflect the larger sample
size in this study or differing PBMC isolation methods.
This is the first study, to our knowledge, to specifically as-
sess the relationship of the Asp358Ala variant with the risk of
COPD, and the first to describe the associations of this variant
with enhanced sIL-6R shedding from neutrophils and enhanced
MCP-1 release from human lung endothelial cells. The COPD co-
horts were well-phenotyped and the genetic analysis results
were robust to sensitivity analyses, including restricting to stud-
ies with data on the proxy variant rs4129267 (i.e. excluding UK
Biobank, the least well-phenotyped study included). As well as
these strengths, our study has some limitations. Although a
large number of COPD cases (n¼ 7,519) and asthma cases
(n¼ 13,157) were included in the analysis, the study only had
80% power to detect an odds ratio of 1.075 or more for COPD and
1.055 or more for asthma. In the genetic analysis, only
summary-level data could be obtained for four out of six of the
studies; however, we were able to closely match the exclusion
criteria and variables adjusted for in the statistical analysis of
the two studies with individual participant data (ECLIPSE and
UK Biobank) to those used in the other four studies. Although
there was no evidence of heterogeneity between the studies
contributing to the Asp358Ala variant-COPD analysis, it is not-
able that the direction of the relationship was the same for all
cohorts except for NETT/NAS. The NETT cohort differs from the
other COPD cohorts in that only patients with both more severe
COPD and emphysema were recruited (37); thus the included
participants are likely to represent a more restricted sub-
phenotype of COPD compared to the other cohorts. Disease out-
comes in the UK Biobank were based on self-reported data
which can be susceptible to misclassification. However, for the
main outcome of COPD, we were able to minimize misclassifica-
tion by only including COPD cases where the self-report was ei-
ther verified in an interview with a trained nurse or where there
was a hospital admission diagnosis of COPD. Further, we used
objective spirometry measures to exclude those with self-
reported COPD who had normal lung function (defined as a ratio
of forced expiratory volume in one second (FEV1)/forced vital
capacity (FVC) 0.7 and a percent predicted FEV1 80).
Analyses of airway function, airway obstruction, asthma and
allergy-related conditions were restricted to UK Biobank data as
information on these outcomes was not available in the COPD
cohorts.
There is strong evidence that inflammation is involved in
the etiology of a number of chronic diseases, yet despite this
and existing evidence for the role of IL-6 in COPD (15), our study
shows no strong evidence for an association between inflam-
mation via IL-6 trans-signaling and the risk of COPD. This is
Figure 3. IL-6R alpha expression in human neutrophils and association of the rs2228145 genotype with secretion of sIL-6R by leukocytes. (A) Serum sIL-6R concentra-
tion from the rs2228145 genotype groups was measured by ELISA. (B) Immunofluorescence of IL-6R alpha AF647and IgG1 AF647 isotype matched control in neutrophils.
Merged images show DAPI and IL-6R AF647 or IgG1 AF647. Magnification x63 with x5 zoom. (C) Expression of IL-6R alpha in neutrophils (NEU) and monocytes (MONO)
analyzed by flow cytometry. Red (unstained), blue (IgG1) and green (IL-6R AF647). Monocytes were gated from the peripheral blood mononuclear cell population based
on their forward scatter and side scatter properties. (D) Immunocytochemistry of IL-6R alpha and IgG1 isotype matched control in neutrophils. Magnification 100.
Data are representative of three independent experiments. (E) sIL-6R release from the rs2228145 genotyped polymorphonuclear neutrophils (PMN) stimulated for
30 min with fMLP or PMA (F,G) sIL-6R release from the rs2228145 genotyped peripheral blood mononuclear cells (PBMCs) stimulated for 30 min with PMA. sIL-6R con-
centrations refer to the difference between stimulated and control levels for B–D. Data represent the median with interquartile range. *P<0.05 using non-parametric
test for trend across groups.
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potentially concordant with recent experimental evidence that
suggests the role of IL-6 trans-signaling in the development of
emphysema occurs independently of inflammatory processes
(29), although replication of the results is needed. Furthermore,
while there is strong evidence that IL-6 serum levels are
increased in COPD patients compared to healthy controls, there
is no evidence of an exposure-response relationship with dis-
ease severity (15) as would be expected in a causal relationship
and as is observed for asthma (17).
More generally, our results, taken together with those
from previous studies, suggest that IL-6 signaling plays a role
in allergic inflammation, potentially contributing to the de-
velopment of atopic asthma phenotypes and other allergy-
related diseases. Mechanistically, this finding is supported by
a number of studies using mouse models and patient sam-
ples. In particular, Doganci and colleagues (38) found that
local blockade of the sIL-6R in an ovalbumin mouse model of
the late-phase asthma response reduced eosinophil numbers
in BALF and decreased levels of the Th2 cytokines IL-4, IL-5,
and IL-13. In a further mouse model, inhalation of cockroach
allergen resulted in an increase in sIL-6R and triggered a type
2/type 17 cytokine profile with mixed eosinophilic-
neutrophilic inflammation in BALF, a response that was atte-
nuated using an anti-IL-6R molecule that selectively blocks
IL-6 trans-signaling (39). In humans with allergic asthma,
sputum sIL-6R levels have been shown to be correlated with
the number of IL-5 producing CD4þT cells following allergen
challenge and IL-6 levels in sputum have been shown to be
associated with a mixed eosinophilic-neutrophilic bronchitis
during exacerbations of asthma (38,40). Furthermore, Ullah
and colleagues (39) have shown that asthmatics with high
(greater than median) levels of IL-6 and IL-6R in the airways
were more likely to have neutrophilic rather than eosino-
philic asthma profiles.
Our findings of enhanced shedding of sIL-6R from neutro-
phils of Asp358Ala homozygotes and an increase in the MCP-
1 release from lung endothelial cells using serum from these
individuals provides evidence of a mechanism through
which IL-6 trans-signaling may contribute to disease sever-
ity in severe, neutrophil-driven, asthma phenotypes. The IL-
6 signaling pathway is an important therapeutic target for
rheumatoid arthritis and Castleman’s disease (41,42), and is
being investigated in clinical trials for other diseases includ-
ing systemic lupus erythematosus (43). Our results support
research into the potential for targeting this pathway to treat
allergic inflammatory conditions, such as severe asthma,
while future research with larger numbers of COPD cases is
needed to understand more fully the role of IL-6 trans-
Figure 4. Effect of sIL-6R trans-signaling on ICAM-1 expression and MCP-1 release from HPAECs. Confluent human pulmonary endothelial cells (HPAECs) were stimu-
lated for 24 h with TNF (5 ng/ml) or sIL-6R (50 ng/ml) 6 IL-6 (50 ng/ml) prior to flow cytometry as described in Materials and Methods. (A) Representative flow cytometry
of ICAM-1 expression in HPAECs after 24 h showing control (red), TNF (green) and sIL-6R þ IL-6 (blue) treatments. (B) Median fluorescence intensity of ICAM-1 expres-
sion. Data are representative of six independent experiments (mean 6 SEM). *P<0.05 using one-way ANOVA across groups. (C) Confluent HPAECs were stimulated for
24 h with TNF (5 ng/ml) or sIL-6R (50 ng/ml)6 IL-6 (50 ng/ml) prior to measurement of secreted MCP-1 by ELISA. Data are representative of five independent experiments
(mean 6 SEM). *P<0.05 using Dunn’s multiple comparison test. (D) Confluent HPAECs were stimulated for 24 h with sIL-6R (50 ng/ml) 6 IL-6 (50 ng/ml), tocilizumab
(TCZ) alone (20lg/ml), IgG alone (20 lg/ml) or IL-6 þ sIL-6R (pre-incubated with 20lg/ml TCZ or 20 lg/ml IgG) and MCP-1 measured by ELISA. Data are representative of
eight independent experiments (mean6 SEM). * P<0.05 using Dunn’s multiple comparison test.
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signaling and its associated pathways in the development of
COPD.
Materials and Methods
Genetic epidemiological study
Participants. Five cohorts contributed data to this study. Data
from participants in the ECLIPSE study were used to estimate
the association between the rs2228145 variant and baseline
serum IL-6 level, and the risk of COPD. Details on this study
have been previously published (44). Briefly, ECLIPSE is a
three-year longitudinal study with data on 2164 people with
well-phenotyped COPD and 582 controls (337 smokers and 245
non-smoker controls). Data on 1,942 participants (1764 people
with COPD and 178 smoker controls) with imputed genetic
data on the rs2228145 and genotyped data on a proxy variant
(rs4129267) were used in the present study. A summary of
baseline characteristics of the ECLIPSE participants by
rs2228145 genotype is given in Supplementary Material, Table
S4. Data from participants in the UK Biobank were used to esti-
mate the association between the rs2228145 and asthma,
allergy-related diseases, airway function, airway obstruction,
and the risk of COPD. The UK Biobank is an open-access re-
source with survey, biomedical and genetic data, and linked
hospital episode statistics data, on approximately 500,000 peo-
ple aged 40 to 69 years at baseline living in the UK. Genotyped
data on rs2228145 from 134,388 participants were available for
this study. Details on the study measures and ascertainment
of outcomes in the UK Biobank are provided in S1 Appendix,
and details on genotyping and genetic QC are available online
(45). This research has been conducted using the UK Biobank
Resource under Application Number 20480. Participants pro-
vided written informed consent to be involved in the cohort. A
summary of baseline characteristics of the UK Biobank partici-
pants by rs2228145 genotype is given in Supplementary
Material, Table S5. Summary statistics for the association be-
tween rs2228145 (and proxy rs4129267) and the risk of COPD
were also available for the COPDGene, the National
Emphysema Treatment Trial (NETT)/Normative Aging Study
(NAS), and GenKOLS studies (37,46–49).
Statistical analyses
Linear regression was used to estimate the association be-
tween the rs2228145 variant and log-transformed baseline
level of serum IL-6 in the ECLIPSE study with adjustment for
age, COPD status, smoking status, smoking amount and ances-
try principal components. Logistic regression was used to esti-
mate the association between the SNPs (rs2228145 and
rs4129267) and COPD separately in each study. The odds ratios
(OR) show the change in risk of COPD per copy of the minor al-
lele and are presented with 95% confidence intervals (95% CI).
Analyses were restricted to former or current smokers and
were adjusted for age, smoking amount and ancestry principal
components. A series of exclusion criteria were applied to the
UK Biobank data to reflect the exclusion criteria used in the
other four studies. This involved excluding participants with
inflammatory-related illness (history of CHD, stroke, diabetes,
or cancer) or other respiratory conditions (history of asthma,
pneumonia, or bronchiectasis). Effect estimates and standard
errors were pooled using inverse-variance weighted fixed-
Figure 5. Serum from Asp358Ala carriers increases MCP-1 release from HPAECs. Confluent HPAECs were cultured for 24 h in the presence of 65% A/A or C/C serum 6 IL-
6 (50 ng/ml) prior to measurement of secreted MCP-1 by ELISA. Data are presented as individual values and means 6 SEM. *P<0.05 using Mann-Whitney test. The inset
shows the association of serum sIL-6R concentration with IL-6 mediated MCP-1 release from HPAECs. Data are presented as individual values for 8 C/C (red circles), 1
C/A (blue circle) and 9 C/C (black circles) samples. Correlation calculated using the Spearman test with the 95% confidence band of the best-fit line.
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effects meta-analysis. A sensitivity analysis was undertaken,
pooling results using random-effects meta-analysis.
Heterogeneity in ORs between studies was quantified using
the I2 statistic (50).
Using data from the UK Biobank only, we also examined the
association between rs2228145 and lung function (measured as
the ratio of forced expiratory volume in one second (FEV1) to
forced vital capacity (FVC)) using linear regression, and the as-
sociations between rs2228145 and binary outcomes of airflow
obstruction (as per definition in (51)), asthma and atopic
asthma, and allergy-related diseases (hay fever, allergic rhinitis
and eczema) using logistic regressions. A proxy for atopic
asthma was defined as having an asthma diagnosis before the
age of 30 years (52) and having either a history of allergic condi-
tions or being a never smoker. These factors have been previ-
ously shown to be predictors of atopic vs. non-atopic asthma
(33). The effect sizes show the change in outcome per copy of
the minor allele and are presented with 95% CIs. Analyses were
adjusted for sex, age, smoking status, smoking amount and an-
cestry principal components.
Power calculations using the Quanto software (53) were
undertaken to estimate the power available for the main ana-
lysis. All other analyses were done using Stata 14.2.
In vitro study
Participants. Thirty seven healthy volunteers were recruited in
the Department of Medicine, Addenbrookes’ Hospital. The age
of blood donors ranged from 22 to 61 years-old and included 17
females and 20 males. All participants gave written informed
consent and the study was approved by the Cambridgeshire 2
Research Ethics Committee (06/Q0108/281).
Reagents. All chemicals were from Sigma-Aldrich (Dorset,
UK), unless otherwise stated. Recombinant sIL-6R and IL-6 were
from PeproTech (London, UK) and tocilizumab (RoActemra,
Roche, Welwyn Garden City, UK). Cell culture reagents were
from Gibco (Paisley, UK).
Genotyping. Blood samples were genotyped by LGC Genomics
at rs2228145 using competitive PCR-based KASPTM technology.
Leukocyte isolation and stimulation
Neutrophils and peripheral blood mononuclear cells (PBMCs)
were isolated from human venous blood using discontinuous
plasma-Percoll gradients as described previously [8] before re-
suspension in IMDM. Cells (20  106/ml) were stimulated for
30 min at 37 C with fMLP (100 nM) or PMA (200 nM).
Supernatants were collected, centrifuged for 5 min (1200g) and
stored at 80 C prior to ELISA measurement.
ELISAs
Human MCP-1 and CXCL8 (IL-8) were measured using matched
antibodies from R&D Systems. Soluble IL-6R was measured
using Europium-Streptavidin as previously described (1). Serum
samples were collected in clot activating tubes (Vacutainer, BD,
UK). IL-6 and MCP-1 in serum was measured using the V-plex
human assay kit (Meso Scale Discovery, MD, Maryland, US) with
a lower limit of detection of 0.06 pg/ml and 0.13 pg/ml
respectively.
Lung endothelial and epithelial cells. Human pulmonary artery
endothelial cells (HPAECs) were from Lonza (Slough, UK) and
stimulated TNF-a (5 ng/ml) or sIL-6R6 IL-6 under growth-factor-
free conditions for 24 h in EBM-2 media (Lonza, Switzerland).
Serum stimulations were performed in EBM-2 media with 65%
serum from A/A or C/C genotyped donors. Human bronchial
epithelial cells (HBECs) were originally derived in the laboratory
of Professor Jerry Shay, and with his permission were gifted to
us by Professor Gisli Jenkins (Nottingham Respiratory Research
Unit, Nottingham City Hospital). The HBECs were incubated
under growth-factor free conditions for 4-24 h with TNF-a (5 ng/
ml) or sIL-6R6 IL-6 prior to collection of supernatants for meas-
urement. For the serum stimulation experiments 65% serum (v/
v) was added to each well to obtain a final sIL-6R concentration
as close to 50 ng/ml in the C/C donors.
Flow cytometry
Trypsinised endothelial cells were collected into a 96 well U-
bottom plate and centrifuged at 400g for 5 min at room tempera-
ture. Cells were resuspended in blocking buffer (5% FBS in 0.5%
BSA) for10 min at 4 C, and incubated in the dark with conju-
gated antibodies (E-selectin-Fluorescein (R&D Systems, UK);
VCAM-1-PECY5 (Biolegend, UK); ICAM-1-APC (BD Biosciences,
UK) or conjugated isotype controls (from R&D Systems,
Biolegend and BD Biosciences respectively) for 30 min at 4 C.
Stained cells were centrifuged at 400g for 5 min at room tem-
perature, and fixed in 1% paraformaldehyde (PFA) in PBS in the
dark at room temperature for 10 min. Fixed cells were centri-
fuged at 400g for 5 min at room temperature, and resuspended
in 400 ll staining buffer (1% FBS and 0.09% sodium azide in PBS).
Detection of cell-bound conjugated antibodies was performed
using a BD FACSCantoTM II (BD Biosciences, UK) and quantifica-
tion was performed using FlowJo software (Tree Star, USA). Data
were acquired from at least 10,000 gated events.
Expression of IL-6R in neutrophils and PBMCs was deter-
mined using IL-6R alpha AF647. Briefly, neutrophils or PBMCs
(5  106/ml) were fixed with CellFIX (BD, Biosciences, UK) for
1 min on ice before incubation with IL-6R alpha AF647 or isotype
control (Biolegend, UK) for 30 min in the dark at 4 C. Data were
acquired from at least 10,000 gated events.
Immunofluorescence and immunocytochemistry
Neutrophils and PBMCs were fixed in 3.5% paraformaldehyde
before three washes in PBS. Cells were cytocentrifuged onto pol-
ylysine slides, permeabilised with Triton-X-100 (0.5%) for 10 min
and rinsed in PBS. Cells were blocked with 0.5% BSA for 30 min
before incubation with antibody sIL-6R AF or isotype control
and staining with DAPI based mountant. Immunofluorescence
was visualized using a fluorescent microscope.
For immunocytochemistry pelleted neutrophils and PBMCs
were placed into induced plasma/thrombin clots, formalin-fixed
overnight and processed into paraffin wax block. 4mm sections
were placed onto adhesive slides and high pH antigen retrieval
performed using a Dako PT Module. Slides were washed in PBS-
Tween, blocked with Hydrogen Peroxidase solution (Dako, UK)
and stained with IL-6R alpha antibody (R&D Systems) or mouse
IgG1 isotype (R&D Systems) control for 1 h at room temperature.
Slides were washed as before, incubated with ENVision Flex
HRP (Dako, UK) for 30 min and visualized with 3,3’-
Diaminobenzedine (Dako, UK) to create a brown reaction prod-
uct, counterstained with haematoxylin and examined by light
microscopy.
Statistical analysis
Data are reported as mean6 standard error of the mean (SEM)
from (n) independent experiments and analyzed using
GraphPad Prism 6.0d software (GraphPad Prism, USA). A P val-
ue<0.05 was considered statistically significant.
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